Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Baskent University School of Medicine, Ankara, Turkey.
Department of Obstetrics and Gynecology, Baskent University School of Medicine, Ankara, Turkey.
Int J Gynaecol Obstet. 2020 Jun;149(3):298-302. doi: 10.1002/ijgo.13147. Epub 2020 Apr 22.
To evaluate the results of receiving no adjuvant treatment (NAT) or radiotherapy after radical hysterectomy in patients with International Federation of Gynecology and Obstetrics 2018 Stage IB1-IB3 cervical cancer with intermediate risk factors.
A retrospective cohort study was conducted at Baskent University School of Medicine's Department of Gynecology and Obstetrics in Ankara, Turkey between January 1, 2008, and December 31, 2016. In total, 134 women with at least two intermediate risk factors (positive LVSI, deep stromal invasion, and tumor size ≥4 cm) were included in the study. Patients were divided into two groups: NAT and radiotherapy.
There were 66 patients in the NAT group and 68 in the radiotherapy group. The median follow-up time was 61.05 months. The 5-year overall survival (OS) rates were similar in both groups (84.1% vs 82.9%, respectively; P=0.57), while the 5-year disease-free survival (DFS) rates were 80.2% and 78.2% in the NAT and radiotherapy groups, respectively (P=0.25). Most importantly, both groups had similar local recurrence rates: 8 (12.1%) in the NAT group and 9 (13.2%) in the radiotherapy group (P=0.82). Multivariant analyses showed that the only independent risk factor for recurrence was tumor size ≥4 cm with a hazard ratio of 2.4 (95% confidence interval 1.12-5.24; P=0.02).
Adjuvant treatment improved neither DFS nor local recurrence rates.
评估在国际妇产科联合会(FIGO)2018 年分期 IB1-IB3 期宫颈癌中,具有中等风险因素的患者在根治性子宫切除术后不接受辅助治疗(NAT)或放疗的结果。
这是一项在土耳其安卡拉的 Baskent 大学医学院妇产科进行的回顾性队列研究。研究时间为 2008 年 1 月 1 日至 2016 年 12 月 31 日。共有 134 名至少有两个中等风险因素(阳性 LVSI、深间质浸润和肿瘤大小≥4cm)的患者纳入本研究。患者被分为 NAT 组和放疗组。
NAT 组有 66 例患者,放疗组有 68 例患者。中位随访时间为 61.05 个月。两组的 5 年总生存率(OS)相似(分别为 84.1%和 82.9%;P=0.57),而 5 年无病生存率(DFS)分别为 80.2%和 78.2%(P=0.25)。最重要的是,两组的局部复发率相似:NAT 组有 8 例(12.1%),放疗组有 9 例(13.2%)(P=0.82)。多变量分析显示,唯一的独立复发危险因素是肿瘤大小≥4cm,风险比为 2.4(95%置信区间 1.12-5.24;P=0.02)。
辅助治疗并未改善 DFS 或局部复发率。